Intraarterial Administration Boosts <sup>177</sup>Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients.
Where this comes from
- Record sourced from PubMed, PMID 34301783.
- Also identified by DOI 10.2967/jnumed.121.262491 and PMC identifier 8978193.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intravenous <sup>177</sup>Lu-high-affinity (HA)-DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intraarterial administration. <b>Methods:</b> Patients underwent at least 1 intravenous <sup>177</sup>Lu-HA-DOTATATE treatment first and subsequent intraarterial cycles. Inpatient and intrapatient comparison was based on posttreatment <sup>177</sup>Lu-HA-DOTATATE imaging 24 h after injection. The technical success rate and adverse events were recorded. <b>Results:</b> Four patients provided informed consent. The technical success rate was 100%, and no angiography-related or unexpected adverse events occurred. Intrapatient comparison showed an increased target lesion accumulation on both planar imaging (mean, +220%) and SPECT/CT (mean, +398%) after intraarterial administration, compared with intravenous administration. No unexpected adverse events occurred during follow-up. <b>Conclusion:</b> Intraarterial peptide receptor radionuclide therapy significantly increases tracer accumulation and is a safe and promising improvement for salvage meningioma patients. Future prospective studies on intraarterial peptide receptor radionuclide therapy are needed to determine the gain in efficacy and survival.
Medical subject headings
- Meningeal Neoplasms
- Meningioma
- Neuroendocrine Tumors
- Organometallic Compounds